Development

Response Pharmaceuticals' RDX-002 shows positive phase 2 results for post-GLP-1 obesity weight management

Virginia-based Response Pharmaceuticals announced 36-week Phase 2 data for RDX-002, a gut-restricted inhibitor of intestinal microsomal triglyceride...

Response Pharmaceuticals Reports Phase 2 Data for RDX-002 Weight Management After GLP-1 Discontinuation

Virginia-based Response Pharmaceuticals announced 36-week Phase 2 data for RDX-002, a gut-restricted inhibitor of intestinal microsomal triglyceride transfer protein (iMTP), in patients who had discontinued GLP-1 receptor agonist therapy for obesity. The Response Pharmaceuticals RDX-002 program targets a specific clinical scenario — post-GLP-1 weight management — where patients commonly regain the majority of lost weight within a year of stopping treatment.

Trial specifics

The Phase 2 study enrolled 68 participants following planned discontinuation of GLP-1 receptor agonist treatment. The trial consisted of a 12-week randomized, double-blind, placebo-controlled period followed by a 24-week open-label extension. The primary endpoint was reduction of postprandial triglyceride response to a standardized high-fat meal, measured by area under the curve. RDX-002 Phase 2 data showed a 93.5% reduction in postprandial triglyceride AUC versus placebo at Week 12 (p<0.001). By Week 36, subjects on RDX-002 preserved 57% of weight loss previously achieved with GLP-1 receptor agonist therapy. Participants who crossed over from placebo to RDX-002 during the open-label extension saw their rate of weight regain fall from 0.58% per week to 0.14% per week. Over the initial 12-week controlled period, total body fat mass gain was 1.99% with RDX-002 versus 6.71% with placebo. Blood pressure and high-sensitivity C-reactive protein also showed treatment-related improvements. The drug was generally well-tolerated; gastrointestinal events — primarily diarrhea, nausea, and abdominal pain — were mild to moderate and largely transient, concentrating in the first two weeks of treatment. One patient in each arm discontinued due to an adverse event, and no serious adverse events were attributed to RDX-002. The specific dosing regimen was not disclosed.

"While GLP-1 agonists are highly effective at reducing weight, 65% of patients discontinue GLP-1 agonist treatment within one year of starting," said Dr. William Sasiela, Chief Medical Officer. The company is now planning a Phase 2 study of RDX-002 in antipsychotic-induced weight gain, a population with elevated cardiometabolic risk. RDX-002 has no prior regulatory approvals; it is being developed under an exclusive worldwide license from Sanofi S.A. and has been studied in more than 450 subjects across multiple Phase I and Phase II trials.

Research context

RDX-002 inhibits MTP selectively within intestinal enterocytes, blocking assembly of chylomicrons and thereby reducing dietary triglyceride and cholesterol absorption. This gut-restricted design distinguishes it from lomitapide (Juxtapid), a systemic MTP inhibitor approved for homozygous familial hypercholesterolemia, which carries hepatotoxicity risks due to hepatic VLDL secretion blockade. By confining activity to the intestine, RDX-002 aims to reduce caloric uptake from fat without systemic lipid accumulation in the liver.

The AllSci BriefSystematic R&D and deal news. Daily.

The obesity treatment after GLP-1 discontinuation setting is increasingly relevant as prescribing of semaglutide (Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) expands. Published data indicate average weight regain of approximately 67% over 52 weeks following GLP-1 receptor agonist cessation. No approved pharmacotherapy currently addresses this long-term weight maintenance drug gap specifically.

RDX-002 occupies a distinct mechanistic niche. No direct competitors targeting intestinal MTP for obesity or post-GLP-1 weight management were identified in the available data. The broader obesity pipeline, however, includes multiple assets with differentiated mechanisms:

  • Eli Lilly's orforglipron, an oral non-peptide GLP-1 receptor agonist in Phase III development for obesity, which could improve adherence but does not specifically address the post-discontinuation setting.
  • Amgen's MariTide (maridebart cafraglutide), a combined GIP receptor antagonist and GLP-1 receptor agonist antibody-peptide conjugate in Phase II trials with monthly dosing designed to reduce treatment burden.
  • Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist in Phase II development as both subcutaneous and oral formulations.

These assets remain within the incretin-based paradigm rather than targeting nutrient absorption. Whether RDX-002's mechanism can serve as a standalone maintenance therapy or would function best in combination with lower-dose GLP-1 receptor agonists remains to be tested in later-stage trials.


Spot something wrong? Report an issue with this article